Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + fulvestrant + ribociclib
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A triple combination therapy consisting of buparlisib (a pan-class I phosphoinositide 3-kinase inhibitor), fulvestrant (a selective estrogen receptor degrader), and ribociclib (a CDK4/6 inhibitor). This combination was investigated for the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer. The combination targets multiple pathways involved in cancer progression but was not advanced to phase II studies due to unexpected toxicity.
- Other names
- buparlisib + ribociclib + fulvestrantribociclib + buparlisib + fulvestrant
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)ESR2 (ERβ)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on buparlisib + fulvestrant + ribociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + fulvestrant + ribociclib.